Epidemiological and clinical features of 125 Hospitalized Patients with COVID-19 in Fuyang, Anhui, China

Ruirui Wang, Min Pan, Xiumei Zhang, Mingfeng Han, Xiaoyun Fan, Fengde Zhao, Manli Miao, Jing Xu, Minglong Guan, Xia Deng, Xu Chen, Leilei Shen, Ruirui Wang, Min Pan, Xiumei Zhang, Mingfeng Han, Xiaoyun Fan, Fengde Zhao, Manli Miao, Jing Xu, Minglong Guan, Xia Deng, Xu Chen, Leilei Shen

Abstract

Objective: To investigate the epidemiological and clinical features of patients with COVID-19 in Anhui province of China.

Method: In this descriptive study, we obtained epidemiological, demographic, manifestations, laboratory data and radiological findings of patients confirmed by real-time RT-PCR in the NO.2 People's Hospital of Fuyang City from Jan 20 to Feb 9, 2020. Clinical outcomes were followed up to Feb 18, 2020.

Results: Of 125 patients infected SARS-CoV-2, the mean age was 38.76 years (SD, 13.799) and 71(56.8%) were male. Common symptoms include fever [116 (92.8%)], cough [102(81.6%)], and shortness of breath [57(45.6%)]. Lymphocytopenia developed in 48(38.4%) patients. 100(80.0%) patients showed bilateral pneumonia, 26(20.8%) patients showed multiple mottling and ground-glass opacity. All patients were given antiviral therapy. 19(15.2%) patients were transferred to the intensive care unit. By February 18, 47(37.6%) patients were discharged and none of patients died. Among the discharged patients, the median time of length of stay was 14.8 days (SD 4.16).

Conclusion: In this single-center, retrospective, descriptive study, fever is the most common symptom. Old age, chronic underlying diseases and smoking history may be risk factors to worse condition. Certain laboratory inspection may contribute to the judgment of the severity of illness.

Keywords: Anhui province; COVID-19; Clinical features; Epidemiological.

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Figures

Fig. 1
Fig. 1
Patients with COVID-19 in Anhui province
Fig. 2
Fig. 2
Timeline of patients with COVID-19 after onset of illness
Fig. 3
Fig. 3
Age of all confirmed patients
Fig. 4
Fig. 4
Age of the critical patients

References

    1. Arabi Y.M., Fowler R., Hayden F.G. Critical care management of adults with community-acquired severe respiratory viral infection. Intensive Care Medicine. 2020
    1. Arabi Y.M., Mandourah Y., Al-Hameed F. Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome. American Journal of Respiratory and Critical Care Medicine. 2018;197(6):757–767.
    1. Cai G. Bulk and single-cell transcriptomics identify tobacco-use disparity in lung gene expression of ACE2, the receptor of 2019-nCov. MedRxiv. 2020
    1. Chen L., Liu H.G., Liu W. Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi. 2020
    1. Chen N., Zhou M., Dong X. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet. 2020;395(10223):507–513.
    1. Dai W., Zhang H., Yu J. CT Imaging and Differential Diagnosis of COVID-19. Canadian Association of Radiologists Journal. 2020
    1. General Office of National Health Commission . 2020. Notice of temporarily naming of the novel coronavirus pneumonia. [EB/OL] 02-08) [2020-02-15]
    1. General Office of National Health Commission, General Office of National Administration of Traditional Chinese Medicine. Diagnostic and treatment protocol for Novel Coronavirus Pneumonia (Trial version 5) [EB/OL]. (2020-02-04) [2020-02-15]. .
    1. Guan Weijie N.Z.H.Y. Clinical characteristics of 2019 novel coronavirus infection in China. MedRxiv. 2020
    1. Huang C., Wang Y., Li X. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395(10223):497–506.
    1. Kangpeng X., Junqiong Z., Feng Y. Isolation and Characterization of 2019-nCoV-like Coronavirus from Malayan. BioRxiv. 2020
    1. La Gruta N.L., Kedzierska K., Stambas J. A question of self-preservation: immunopathology in influenza virus infection. Immunology and Cell Biology. 2007;85(2):85–92.
    1. D.T.W.Y.L.H. Lee Factors associated with psychosis among patients with severe acute respiratory syndrome a case-control study. Clin Infect Dis. 2004
    1. Li X., Wang L., Yan S. Clinical characteristics of 25 death cases with COVID-19: a retrospective review of medical records in a single medical center, Wuhan, China. MedRxiv. 2020
    1. Li Y.M., Wang S.X., Gao H.S. Factors of avascular necrosis of femoral head and osteoporosis in SARS patients’ convalescence. Zhonghua Yi Xue Za Zhi. 2004;(16):33–38.
    1. Lim J., Jeon S., Shin H. Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR. Journal of Korean Medical Science. 2020;35(6)
    1. Liu P., Chen W., Chen J. Viral Metagenomics Revealed Sendai Virus and Coronavirus Infection of Malayan Pangolins (Manis javanica) Viruses. 2019;11(11):979.
    1. Lu R., Zhao X., Li J. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The Lancet. 2020
    1. Mair-Jenkins J., Saavedra-Campos M., Baillie J.K. The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysis. Journal of Infectious Diseases. 2014;211(1):80–90.
    1. National Health Commission of the People’s Republic of China . 2020. What is fecal-oral transmission? [EB/OL] 02-08) [2020-02-15].
    1. Ni Y., Chen G., Sun J. The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis. Critical Care (London, England) 2019;23(1):99.
    1. Novel Coronavirus Pneumonia Emergency Response Epidemiology Team The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41:145–151.
    1. Russell C.D., Millar J.E., Baillie J.K. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet (London, England) 2020;395(10223):473–475.
    1. Tian H., Liu Y., Li Y. The impact of transmission control measures during the first 50 days of the COVID-19. MedRxiv. 2020
    1. Wang D., Hu B., Hu C. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. Jama. 2020
    1. World Health Organization . 2004. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003[EB/OL] 04-21) [2020-02-15].
    1. World Health Organization . 2020. Coronavirus disease 2019 (COVID-19) Situation Report-61[EB/OL] 03-21) [2020-03-22]. 2.
    1. World Health Organization, 2019: World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV) [EB/OL]. (2019-11-30) [2020-02-18]. .
    1. World Health Organization . 2020. Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected [EB/OL] 01-28) [2020-02-18].
    1. Xiao J.Z., Ma L., Gao J. Glucocorticoid-induced diabetes in severe acute respiratory syndrome: the impact of high dosage and duration of methylprednisolone therapy. Zhonghua Nei Ke Za Zhi. 2004
    1. Xu X., Chen P., Wang J. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Science China. Life Sciences. 2020
    1. Zhu N., Zhang D., Wang W. A Novel Coronavirus from Patients with Pneumonia in China, 2019. The New England Journal of Medicine. 2020

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa